DSIP 10 mg

DSIP 5 mg – Peptide Hubs

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide that has been studied extensively for its role in promoting sleep, regulating hormonal release, and reducing stress responses in laboratory models. The 5 mg lyophilized format from Peptide Hubs offers researchers a high-purity option for studying DSIP's effects on circadian rhythms, neurological recovery, and endocrine system balance.

What Is DSIP?

DSIP is a small peptide first discovered in the 1970s in the hypothalamus of rabbits, where it demonstrated the ability to induce slow-wave sleep. Since then, it has been the focus of numerous experimental models investigating its impact on sleep architecture, cortisol regulation, and oxidative stress mitigation. Research also indicates possible benefits in neuroprotection and recovery from physical and psychological stressors.

Mechanism of Action

Although DSIP's full mechanisms are still under investigation, it's believed to act on the hypothalamic-pituitary-adrenal (HPA) axis, modulating sleep cycles and neuroendocrine function. It may influence melatonin secretion and reduce corticotropin-releasing hormone (CRH), helping to improve sleep quality. For more, see this NIH study on DSIP and sleep function.

Research Applications

DSIP 10 mg is used in studies focused on:

• Regulation of circadian rhythms and sleep-wake cycles
• Reduction of stress-induced hormonal disruption
• Neurological recovery post-trauma or fatigue
• Modulation of pain response and neuroinflammation

Some researchers also investigate its synergy with Semax in models of cognitive fatigue and recovery. Others explore DSIP alongside GHK-CU or B7-33 to examine inflammation-related interactions during rest cycles.

Suggested Experimental Use

• Dosage Range: 100–500 mcg daily in lab models
• Delivery Method: Subcutaneous or intranasal depending on design
• Cycle Duration: 5–14 days for sleep rhythm protocols

Peptide Stacking Options

DSIP is often stacked with other neuro-supportive or recovery-focused compounds. Common combinations in research include:

• Cardiogen 20 mg – for heart-brain axis recovery post-sleep deprivation
• Cartalax 20 mg – for joint recovery and inflammation during deep sleep states
• Chonluten 20 mg – for immune and lung recovery during rest

Safety Profile

DSIP is considered safe in laboratory settings. It does not influence androgenic or estrogenic pathways, does not aromatize, and is non-toxic to the liver. It is free from cardiovascular or blood pressure risks and has shown no hepatotoxic effects in preclinical studies.

Legal Status

DSIP is not approved by the FDA and is strictly sold for laboratory and research use. It must not be used in humans or animals outside regulated protocols. To follow developments in DSIP research, visit the ClinicalTrials.gov registry.

Frequently Asked Questions